Cancer treatment via epidermal growth factor receptor (EGFR)–targeted therapies has been used increasingly over the last years owing to their lower overall toxic effect profile and higher therapeutic efficacy than conventional cytotoxic drugs.1 Approximately two-thirds of patients treated with EGFR inhibitors (EGFRIs) develop skin reactions.2 However, since the skin reactions appear to be associated with a better response rate to EGFRI treatment and a better overall survival rate,1,2 continuation of treatment despite the cutaneous adverse effects is recommended and important. As the cause of the skin changes is still unclear, no cause-based treatment options exist.
Eiling E, Brandt M, Schwarz T, Hauschild A. Pimecrolimus: A Novel Treatment for Cetuximab-Induced Papulopustular Eruption. Arch Dermatol. 2008;144(9):1236-1238. doi:10.1001/archderm.144.9.1236